Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPN | P05981 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130104 | 1.00 | ALDH1A1 (0.53) | ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1464202 | 1.00 | ALDH1A1 (0.53) | ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL10193067 | 1.00 | ALDH1A1 (0.53) | ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29500256 | 1.00 | ALDH1A1 (0.53) | ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL472429 | 1.00 | ALDH1A1 (0.53) | ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL258422 | 1.00 | ALDH1A1 (0.53) | ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2239236 | 1.00 | ALDH1A1 (0.53) | ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13050357 | 1.00 | ALDH1A1 (0.53) | ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7089968 | 0.98 | ALDH1A1 (0.52) | ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1 | |
| P-Xylene SCHEMBL5424500 | 0.98 | ALDH1A1 (0.52) | ALDH1A1NPSR1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 558 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115803318-B | Method for preparing a compound | 拜耳公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260070891-A1 | METHOD FOR PRODUCING QUINOXALINE DERIVATIVE | KYOWA KIRIN CO., LTD. (JP) | 2026-03-12 | — | — | US | claimed |
| EP-4582419-A1 | METHOD FOR PRODUCING QUINOXALINE DERIVATIVE | Kyowa Kirin Co., Ltd. (JP) | 2025-07-09 | — | — | EP | claimed |
| CN-119613311-A | High-selectivity synthesis method of (3S, 4R) -3- (N-benzyl-N-cyclopropyl) aminomethyl-4-hydroxypyrrolidine-1-carboxylic acid benzyl ester | 武汉理工大学 | 2025-03-14 | — | — | CN | claimed |
| CN-118344314-A | Method for safely preparing gamma-valerolactone by taking formic acid as hydrogen source | 南京工业大学 | 2024-07-16 | — | — | CN | claimed |
| EP-4392426-A1 | SOLID FORMS OF SPIROTRICYCLIC APOL1 INHIBITORS AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-07-03 | — | — | EP | claimed |
| US-20240116916-A1 | METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 2-[2-(2-CHLOROTHIAZOL-5-YL)-2-HYDROXY-ETHYL]SULFANYL-6-HYDROXY-3-METHYL-5-PHENYL-PYRIMIDIN-4-ONE | BASF SE (DE) | 2024-04-11 | — | — | US | claimed |
| CN-115650824-B | Chiral diol and preparation method thereof, prepared catalyst and preparation method and application thereof | 合肥工业大学 | 2024-01-23 | — | — | CN | claimed |
| CN-115803318-A | Process for the preparation of (5S) -5- ({ 2- [4- (butoxycarbonyl) phenyl ] ethyl } [2- (2- { [ 3-chloro-4' - (trifluoromethyl) [ biphenyl ] -4-yl ] methoxy } phenyl) ethyl ] amino) -5,6,7,8-tetrahydroquinoline-2-carboxylic acid butyl ester | 拜耳公司 | 2023-03-14 | — | — | CN | claimed |
| WO-2023028237-A1 | SOLID FORMS OF SPIROTRICYCLIC APOL1 INHIBITORS AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2004085058-A1 | PROCESS TO PRODUCE ENANTIOMERICALLY ENRICHED ALCOHOLS AND AMINES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-07 | — | — | WO | claimed |
| US-20040030181-A1 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | claimed |
| US-20030225153-A1 | Process for preparing arylaminopropanols | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-04 | — | — | US | claimed |
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-04 | — | — | US | claimed |
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | KANEKA CORPORATION (JP) | 2003-07-10 | — | — | US | claimed |
| EP-0915076-B1 | Process for the preparation of trans-(R,R)-actinol | HOFFMANN LA ROCHE (CH) | 2002-01-16 | — | — | EP | claimed |
| EP-1153919-A1 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 AGONIST BY THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2001-11-14 | — | — | EP | claimed |
| US-6187961-B1 | HYDROGENATING (R)-LEVODIONE IN PRESENCE OF HYDROGEN DONAR AND A SOLVENT OR IN PRESENCE OF HYDROGEN DONOR WHICH SIMULTANEOUSLY USED AS THE SOLVENT, AND AN AMINO-AMIDE-RUTHENIUM COMPLEX | ROCHE VITAMINS INC. | 2001-02-13 | — | — | US | claimed |
| CN-1223998-A | Process for producing trans- (R, R) -actinol | HOFFMANN LA ROCHE (CH) | 1999-07-28 | — | — | CN | claimed |
| EP-0915076-A1 | Process for the preparation of trans-(R,R)-actinol | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | ADRB3, ADRB2, ADRB1 | ALDH1A1 184/4885NPSR1 284/4885SLC1A3 1594/4885 |
| US-20030225153-A1 | Process for preparing arylaminopropanols | AHR, CYP1A1, CYP1A2 | ALDH1A1 233/4885NPSR1 1011/4885SLC1A3 1292/4885 |
| US-20040030181-A1 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | HPD, GRHPR, CYP4B1 | ALDH1A1 133/4885NPSR1 2715/4885SLC1A3 1357/4885 |
| US-20240116916-A1 | METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 2-[2-(2-CHLOROTHIAZOL-5-YL)-2-HYDROXY-ETHYL]SULFANYL-6-HYDROXY-3-METHYL-5-PHENYL-PYRIMIDIN-4-ONE | TPMT, UGT1A8, BHMT2 | ALDH1A1 233/4885NPSR1 4174/4885SLC1A3 1424/4885 |
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | GRHPR, HPD, HAAO | ALDH1A1 273/4885NPSR1 2556/4885SLC1A3 752/4885 |
| US-20260070891-A1 | METHOD FOR PRODUCING QUINOXALINE DERIVATIVE | ME1, PYM1, ME3 | ALDH1A1 2714/4885NPSR1 3733/4885SLC1A3 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.